Effect of Costus igneus: The insulin plant, on prediabetes and diabetes in neonatal streptozotocin rats
Introduction: Pre-diabetes is a condition that persists for a considerable duration before progressing into type 2 diabetes mellitus (T2DM). Development of resistance to insulin is the underlying cause of pre-diabetes, preventive measures such as diagnosis, treatment and exercise will preclude its development into T2DM. The present study aims at studying the effect of pre-treatment and post-treatment with isolated fraction of Costus igneus on pre-diabetes and diabetes in neonatal streptozotocin (STZ) induced T2DM.
Methods: Neonatal rats were treated with STZ and differentiated for pre-treatment and post-treatment. Rats of pre-treated group were treated with isolated fraction of Costus igneus (CIF) from 4th week after STZ administration and after 12th week in non-treated rats of post-treatment group. The antihyperglycemic was studied on 7th and 12th week after STZ treatment using oral glucose tolerance test and the hypoglycemic effect was studied on day 1, 7, 14 and 21 of treatment after 12th week of STZ treatment in both pre and post treated groups.
Results: Oral glucose tolerance test on 7th and 12th week had shown a protective effect against increase in blood glucose levels in pre-treated groups whereas, no such significant decrease was observed in non-treated groups. In the effect on hypoglycemia, a reduction in blood glucose levels was observed on treatment with CIF in both pre and post treated rats on 14th and 21st day.
Conclusions: Treatment with CIF in pre-diabetic stage could reduce the chances of progression into T2DM and is also beneficial in diabetic rats, which could be due to increase in the peripheral utilization of glucose and the insulin mimetic effect of Costus igneus.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diab Care 2006;29:43-8.
3. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the baltimore longitudinal study of aging. Diabetes 2003;52:1475-84.http://dx.doi.org/10.2337/diabetes.52.6.1475
4. Sushma N, Raju AB. Pre-diabetes: A Review. IntJBiomedRes2011;2161-70.
5. Horton R. Prediabetes and the potential to prevent diabetes. Lancet 2012;379:2213.http://dx.doi.org/10.1016/S0140-6736(12)60960-X
6. Scheen AJ. Pathophysiology of type 2 diabetes.ActaClinBelg 2003;58:335-41.http://dx.doi.org/10.1179/acb.2003.58.6.001
7. Polyzos SA, Koutouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. CurrMol Med 2009;9:299-314.http://dx.doi.org/10.2174/156652409787847191
8. Li S, Shin HJ, Ding EL, van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 2009;302:179-88.http://dx.doi.org/10.1001/jama.2009.976
9. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends in Endocrinolmetabol 2003;14:137–45.http://dx.doi.org/10.1016/S1043-2760(03)00024-9
10. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Parikka PI,et al.,Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance. N Engl J Med 2001;344:1343-50.http://dx.doi.org/10.1056/NEJM200105033441801
11. The top 10 causes of death (World Health Organization) (Internet). 2008 (Updated Jun 2011; cited Dec 2012). Available from: http://who.int/mediacentre/factsheets/fs310/en
12. Patel DK, Prasad SK, Kumar R, HemalathaS. An overview on antidiabetic medicinal plants having insulin mimetic property. Asia Pacific JTrop Biomed 2012;2:320-30.http://dx.doi.org/10.1016/S2221-1691(12)60032-X
13. Gray AM, Flatt PR. Actions of the traditional anti-diabetic plant, Agrimony eupatoria (agrimony): effects on hyperglycaemia, cellular glucose metabolism and insulin secretion. Br J Nutr 1998;80:109-14.http://dx.doi.org/10.1017/S0007114598001834
14. Gupta RN, Pareek A, Suthar M, Rathore GS, Basniwal PK, Jain D. Study of glucose uptake activity of Helicteresisora Linn. fruits in L-6 cell lines. Int J Diabetes Dev Ctries. 2009;29:170-73.http://dx.doi.org/10.4103/0973-3930.57349
15. Ludvik B, Waldhausl W, Prager R, Kautzky-Willer A, Pacini G. Mode of action of ipomoea batatas (Caiapo) in type 2 diabetic patients.Metabol 2003;52:875-80.http://dx.doi.org/10.1016/S0026-0495(03)00073-8
16. Fatima A, Agarwal P, Singh PP. Herbal option for diabetes: an overview. Asia Pacific J Trop Dis 2012;2:536-44.http://dx.doi.org/10.1016/S2222-1808(12)60216-3
17. Vishnu B, Naveen A, Akshay K, Mukesh S, Patil MB. Antidiabetic activity of insulin plant (Costus igneus) leaf extract in diabetic rats. J Phar Res 2010;3:608-12.
18. Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol res 2001;50:536-46.
19. Kandhare AD, Raygude KS, Kumar VS, Rajmane AR, Visnagri A, Ghule AE et al., Ameliorative effects quercetin against impaired motor nerve function, inflammatory mediators and apoptosis in neonatal streptozotocin-induced diabetic nephropathy in rats. Biomed Aging Pathol 2012;2:173-86.http://dx.doi.org/10.1016/j.biomag.2012.10.002
20. Liu WJ. Traditional Herbal Medicine Research Methods: Identification, Analysis, Bioassay, Pharmaceutical and clinical Studies. New Jersey:, John Wiley & Sons Inc; 2011.http://dx.doi.org/10.1002/9780470921340
21. Edwin JE, Joshi SB, Jain DC. Antidiabetic activity of flower buds of Micheliachampacalinn. Ind J Pharmacol 2008;40:256-60.http://dx.doi.org/10.4103/0253-7613.45151
22. Andrade Cetto A, MartínezZurita E, Soto Constantino A, Revilla Monsalve C, Wiedenfeld H. Chronic hyperglycemic effect of Malmeadepressa root on n5-streptozotocin diabetic rats. J Ethnopharmacol 2008;116:358-62.http://dx.doi.org/10.1016/j.jep.2007.11.043
23. Mazumer PM, Farswan M, Parcha V. Effect of isolated active compound (CG-1) of Cassia glauca leaf on blood glucose, lipid profile and atherogenic index in diabetic rats. Ind J Pharmacol 2009;41:182-6.http://dx.doi.org/10.4103/0253-7613.56076
24. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diab Care 1995;18:258-68.http://dx.doi.org/10.2337/diacare.18.2.258
25. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone?.Diab care 2003;26:2442-50.http://dx.doi.org/10.2337/diacare.26.8.2442
26. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998;15:539-53.http://dx.doi.org/10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S
27. Ryden L. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. Eur Heart J 2007;28:88-136.
28. Wang Y, Xin X, Zhendong J, Yan H, Xianhui L, Jianzhao W, Manwen J. Anti-diabetic effects of pentamethylquercetin in neonatallystreptozotocin-induced diabetic rats. Eur J Pharmacol 2011;668:347-53.http://dx.doi.org/10.1016/j.ejphar.2011.06.022
29. Xiaochen H, Juichi S, Yoshiharu O, Ming X, Gustavo B, Yuzo S. Effect of Gosha-jinki-gan (Chinese herbal medicine: Niu-Che-Sen-Qi-Wan) on insulin resistance in streptozotocin-induced diabetic rats. Diab Res clinprac 2003;59:103-11.http://dx.doi.org/10.1016/S0168-8227(02)00203-6
30. Julie T, Magaly AM, Sidney BP, et al., Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. Metabol 2007;56;977-84.http://dx.doi.org/10.1016/j.metabol.2006.05.021
31. Ahren B. Insulin secretion in neonatallystreptozotocin-injected mice. Diab Res 1989;11:185-90.
This work is licensed under a Creative Commons Attribution 4.0 International License.